ADAR1 Capital Management’s Context Therapeutics CNTX Stock Holding History

ADAR1 Capital Management’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$920K	Hold	351,094	–	–	0.05%	166
2025 Q4	$516K	Hold	351,094	–	–	0.04%	182
2025 Q3	$340K	Hold	351,094	–	–	0.03%	159
2025 Q2	$230K	Hold	351,094	–	–	0.04%	152
2025 Q1	$215K	Hold	351,094	–	–	0.04%	144
2024 Q4	$369K	Sell	351,094 -22,741	-6%	-$39.4K	0.07%	125
2024 Q3	$733K	Sell	373,835 -271,326	-42%	-$602K	0.12%	95
2024 Q2	$1.29M	Buy	645,161 +439,227	+213%	+$757K	0.24%	57
2024 Q1	$284K	Buy	+205,934	New	+$232K	0.06%	106

Other funds holding CNTX

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

ADAR1 Capital Management's CNTX Position: Q1 2026 in Review

ADAR1 Capital Management held its Context Therapeutics (CNTX) position steady in Q1 2026 at 351,094 shares worth $920K. The position accounts for 0.05% of the portfolio, ranked #166.

ADAR1 Capital Management first reported a position in CNTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.29M in Q2 2024. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

ADAR1 Capital Management held 351,094 shares of Context Therapeutics worth $920K as of Q1 2026.
ADAR1 Capital Management left its Context Therapeutics share count unchanged in Q1 2026.
Context Therapeutics made up 0.05% of ADAR1 Capital Management's portfolio in Q1 2026, its #166 holding.
ADAR1 Capital Management first reported a position in Context Therapeutics in Q1 2024 and has held it in 9 quarters since.
ADAR1 Capital Management's Context Therapeutics position peaked at $1.29M in Q2 2024.
59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.